Merck wins approval for cancer drug acquired in 2019 biotech buyout
Peloton was one of a handful of cancer-focused biotech companies acquired since 2018 by Merck, which has sought to complement its top-selling immunotherapy Keytruda w...
From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement